Results 41 to 50 of about 3,507,735 (293)

The development of improved and new in vitro assays for detecting the genotoxic and non-genotoxic carcinogenic potential of chemicals in the discovery phase of drug development [PDF]

, 2011
In drug development, toxicity is an important factor for attrition, resulting in a failure rate of 30%-40%. Hepatotoxicity, nephrotoxicity, cardiovascular safety, reproduction toxicity, developmental toxicity (teratogenicity), genotoxicity and ...
Westerink, W.M.A.
core  

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

Viruses, 2023
In the early stages of drug discovery, researchers develop assays that are compatible with high throughput screening (HTS) and structure activity relationship (SAR) measurements.
Ralph A. Tripp, David E. Martin
doaj   +1 more source

Ovarian Sex Cord Stromal Tumors in Children and Adolescents—The European Standard Clinical Practice Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider, Kris‐Ann Schultz, Nora Schnitzler, Michael Abele, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Ines B. Brecht, Maja Cesen, Andrea Ferrari, Michaela Kuhlen, Malgorzata A. Krawczyk, Ricardo Lopez‐Almaraz, Yves Reguerre, Calogero Virgone, Daniel Orbach   +15 more
wiley   +1 more source

Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data

Scientific Reports
Even though head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, there are only two PD-1 targeted immunotherapies (pembrolizumab and nivolumab) and one tumor intrinsic EGFR targeted therapy (cetuximab) that are FDA ...
Daniel Bottomly, Chase Mathieson, Myles Vigoda, Sophia Jeng, Nathaniel Evans, Ashley Anderson, Aurora Blucher, Aletha Lesch, Christina Zheng, Ted Laderas, James Jacobs, Molly Kulesz-Martin, Shannon McWeeney   +12 more
doaj   +1 more source

Early Body Mass Index z‐Score Change and Resolution of Severe Malnutrition in Children With Sickle Cell Anemia in a Low‐Income Setting: A Prospective Single‐Arm Extension Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with sickle cell anemia (SCA) in low‐income settings are at risk of severe malnutrition, but optimal nutritional management has not been established. We evaluated an intensified ready‐to‐use therapeutic food (RUTF) regimen in children with persistent severe malnutrition after initial treatment and assessed whether early ...
Safiya Gambo, Shehu Umar Abdullahi, Hassan Adam Murtala, Halima Kabir, Khadija A. Shamsu, Sari A. Acra, Virginia A. Stallings, Mark Rodeghier, Michael R. DeBaun, Lauren J. Klein   +9 more
wiley   +1 more source

Design and fabrication of novel microfluidic-based droplets for drug screening on a chronic myeloid leukemia cell line.

PLoS ONE
BackgroundThe challenges associated with traditional drug screening, such as high costs and long screening times, have led to an increase in the use of single-cell isolation technologies.
Niloofar Jaafari, Amir Asri Kojabad, Rima Manafi Shabestari, Majid Safa   +3 more
doaj   +1 more source

1st Joint European Conference on Therapeutic Targets and Medicinal Chemistry (TTMC 2015)

Pharmaceuticals, 2015
The European Conference on Therapeutic Targets and Medicinal Chemistry is a new two-day meeting on drug discovery that is focused on therapeutic targets and the use of tools to explore all fields of drug discovery and drug design such as molecular ...
Marc Le Borgne, Samer Haidar, Olivier Duval, Bernhard Wünsch, Joachim Jose   +4 more
doaj   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine, Hallie Coltin, Sylvia Cheng, Lucie Lafay‐Cousin, Vanan Issai Magimairajan, Craig Erker, Stéphanie Vairy, Lynette Bowes, Adam Fleming, Donna Johnston, Sarah McKillop, Roona Sinha, Julie Bennett, Christina Coleman, Laura Wheaton, Shayna Zelcer, Samuele Renzi, Thai Hoa Tran   +17 more
wiley   +1 more source

Drug-drug interactions in the hospital [PDF]

, 2007
Introduction Drug interaction screening programs are an important tool to check prescriptions of multiple drugs for potential drug-drug interactions (pDDIs). Several programs are available on the market.
Vonbach, Priska
core   +1 more source

Organoid-on-Chip Technologies in Precision Oncology: Bridging Patient-Specific Tumor Biology and Physiologically Relevant Drug Screening

Organoids
The inadequacy of traditional preclinical oncology models, specifically two-dimensional (2D) monolayer cultures and murine in vivo systems, in predicting human drug responses has led to the development of patient-derived organoids (PDOs) and microfluidic
Muhammet Volkan Bulbul, Turan Demircan
doaj   +1 more source